



Express Mail Nos. EM245163145US and EM245163110US

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/526,108
				Filing Date	May 10, 2006
				First Named Inventor	Sabine Maier
				Art Unit	1634
				Examiner Name	Amanda Marie Shaw
Sheet	1	of	3	Attorney Docket Number	47675-102

U.S. PATENT DOCUMENTS						
Examine r Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ¹ (if known)				
		US- 5744305	04-28-1998	Fodor et al.		
		US- 5837832	11-17-1998	Chee et al.		
		US- 6331393	12-18-2001	Laird et al.		
FOREIGN PATENT DOCUMENTS						
Examine r Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		DE 10239313.3	08-27-2002	Epigenomics AG		
		DE 10255104.9	11-26-2002	Epigenomics AG		
		WO 95/00669	01-05-1995	Pharmacia Biotech AB		
		WO 95/15373	06-08-1995	McGill University		
		WO 97/45560	12-04-1997	North Shore University Hospital Research Corp.		
		WO 97/46705	12-11-1997	Johns Hopkins University School of Medicine		
		WO 99/28498	06-10-1999	Epigenomics GMBH		
		WO 01/29262	04-26-2001	Orchid Biosciences, Inc.		
		WO 01/40521	06-07-2001	Curagen Corp.		
		WO 01/77373	10-18-2001	Epigenomics AG		
		WO 02/38801	05-16-2002	Human Genetic Signatures Pty Ltd		
		WO 02/059347	08-01-2002	Johns Hopkins University School of Medicine		
		WO 02/070742	09-12-2002	Epigenomics AG		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AS/

Examiner Signature	/Amanda Shaw/	Date Considered	02/23/2009
-----------------------	---------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/526,108
				Filing Date	May 10, 2006
				First Named Inventor	Sabine Maier
				Art Unit	1634
				Examiner Name	Amanda Marie Shaw
Sheet	2	of	3	Attorney Docket Number	47675-102

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CALLAHAN et al., "The Genetic Pathology of Breast Cancer," Progress in Clinical and Biological Research, 1992, pp. 117-136, Volume 376	
		CALLAHAN et al., "Somatic Mutations and Human Breast Cancer," Cancer Supplement, March 15, 1992, pp. 1582-1588, Volume 69, No. 6	
		CHEICKH et al., "An Attempt to Define Sets of Cooperating Genetic Alterations in Human Breast Cancer," International Journal of Cancer, 1992, pp. 542-547, Volume 51	
		CHEN et al., "Heterogeneity for Allelic Loss in Human Breast Cancer," Journal of the National Cancer Institute, 1992, pp. 506-510, Volume 84	
		DE IORIO et al., "Implication of Laminin and Collagen Type IV Expression in the Progression of Breast Carcinoma," Anticancer Research, March-April 2001, pp. 1395-1399, Volume 21, No. 2B	
		EADS et al., "Epigenetic Patterns in the Progression of Esophageal Adenocarcinoma," Cancer Research, April 15, 2001, pp. 3410-3418, Volume 61	
		FEIL et al., "Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing," Nucleic Acids Research, 1994, pp. 695-696, Volume 22, No. 4	
		GITAN et al., "Methylation-Specific Oligonucleotide Microarray: A New Potential for High-Throughput Methylation Analysis," Genome Research, 2001, pp. 158-164, Volume 12	
		GONZALGO et al., "Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE), Nucleic Acids Research, 1997, pp. 2529-2531, Volume 25, No. 12	
		GRIGG et al., "Sequencing 5-Methylcytosine Residues in Genomic DNA," BioEssays, June 1994, pp. 431-436, Volume 16, No. 6	
		GUT et al., "DNA and Matrix Assisted Laser Desorption Ionization Mass Spectrometry," Molecular Biology: Current Innovations and Future Trends, 1995, pp. 147-157, Horizon Scientific Press, Wymondham, United Kingdom	
		GUT et al., "A procedure for selection DNA alkylation and detection by mass spectrometry," Nucleic Acids Research, 1995, pp. 1367-1373, Volume 23, No. 8	
		HEID et al., "Real Time Quantitative PCR," Genome Research, 1996, pp. 986-994, Volume 6	
		HUANG et al., "Methylation profiling of CpG islands in human breast cancer cells," Human Molecular Genetics, 1999, pp. 459-470, Volume 8, No. 3	
		KARAS et al., "Laser Desorption Ionization of Proteins with Molecular Masses Exceeding 10 000 Daltons," Analytical Chemistry, October 15, 1988, pp. 2299-2301, Volume 60, No. 20	
		KING et al., "Heterogeneous Expression of erbB-2 Messenger RNA in Human Breast Cancer," Cancer Research, August 1, 1989, pp. 4185-4191, Volume 49	
		MARTIN et al., "Genomic sequencing indicates a correlation between DNA hypomethylation in the 5' region on the pS2 gene and its expression in human breast cancer cell lines," Gene, 1995, pp. 261-264, Volume 157	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AS/

Examiner Signature	/Amanda Shaw/	Date	02/23/2009
		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/526,108		
		Filing Date	May 10, 2006		
		First Named Inventor	Sabine Maier		
		Art Unit	1634		
		Examiner Name	Amanda Marie Shaw		
Sheet	3	of	3	Attorney Docket Number	47675-102

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MODEL et al., "Feature selection for DNA methylation based cancer classification," Bioinformatics, 2001, pp. S157-S164, Volume 17, Supplement 1	
		OLEK et al., "A modified and improved method for bisulphite based cytosine methylation analysis," Nucleic Acids Research, 1996, pp. 5064-5066, Volume 24, No. 24	
		OLEK et al., "The pre-implantation ontogeny of the H19 methylation imprint," Nature Genetics, November 1997, pp. 275-276, Volume 17	
		PHAROAH et al., "Polygenic susceptibility to breast cancer and implications for prevention," Nature Genetics, May 2002, pp. 33-36, Volume 31, No. 1	
		REIN et al., "Identifying 5-methylcytosine and related modifications in DNA genomes," Nucleic Acids Research, 1998, pp. 2255-2264, Volume 26, No. 10	
		SANGER et al., "DNA sequencing with chain-terminating inhibitors," PNAS, December 1977, pp. 5463-5467, Volume 74, No. 12	
		VAN 'T VEER et al., "Gene expression profiling predicts clinical outcome of breast cancer," Nature, January 31, 2002, pp. 530-536, Volume 415, No. 6871	
		XIONG et al., "COBRA: a sensitive and quantitative DNA methylation assay," Nucleic Acids Research, 1997, pp. 2532-2534, Volume 25, No. 12	
		YAN et al., "Dissecting Complex Epigenetic Alterations in Breast Cancer Using CpG Island Microarrays," Cancer Research, December 1, 2001, pp. 8375-8380, Volume 61	
		YU et al., "Specific Inhibition of PCR by Non-Extendable Oligonucleotides Using a 5' to 3' Exonuclease-Deficient DNA Polymerase," BioTechniques, October 1997, pp. 714-720, Volume 23	
		ZESCHNIGK et al., "Imprinted segments in the human genome: different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method," Human Molecular Genetics, 1997, pp. 387-395, Volume 6, No. 3	
		ZESCHNIGK et al., "A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus," European Journal of Human Genetics, March-April 1997, pp. 94-98, Volume 5, No. 2	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AS/

Examiner Signature	/Amanda Shaw/	Date	02/23/2009
		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.